Understanding how antibodies affect a key enzyme in a rare blood disorder
Exploring the mechanisms of action of anti-ADAMTS 13 antibodies in immune thrombotic thrombocytopenic purpura
This study is looking at how certain antibodies in people with immune thrombotic thrombocytopenic purpura (iTTP) mistakenly attack an important enzyme that helps prevent dangerous blood clots, with the goal of finding better ways to diagnose and treat this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10914674 on NIH RePORTER |
What this research studies
This research investigates immune thrombotic thrombocytopenic purpura (iTTP), a serious blood disorder caused by the body's immune system mistakenly attacking the enzyme ADAMTS13. The study focuses on how specific antibodies inhibit this enzyme's function, which is crucial for preventing harmful blood clotting. By examining the mechanisms of these antibodies, researchers aim to uncover how they interfere with the enzyme's ability to process von Willebrand factor, a protein essential for blood clotting. This could lead to better diagnostic and therapeutic strategies for patients suffering from iTTP.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with immune thrombotic thrombocytopenic purpura.
Not a fit: Patients with other types of blood disorders unrelated to ADAMTS13 or iTTP may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and management strategies for patients with immune thrombotic thrombocytopenic purpura.
How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of antibody interactions with enzymes, suggesting potential for success in this area.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Halkidis, Konstantine — University of Kansas Medical Center
- Study coordinator: Halkidis, Konstantine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.